Int J Antimicrob Agents. 2023 Apr 21:106825. doi: 10.1016/j.ijantimicag.2023.106825. Online ahead of print.
ABSTRACT
INTRODUCTION: ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) in patients hospitalized in intensive care units (ICU) is an important and challenging complication, including in COVID-19 patients. Considering the poor lung penetration of most antibiotics, including intravenous colistin due to the poor PK/PD at the infection site, the choice of the best antibiotic regimen is still being debated.
METHODS: this was a single-center, observational study conducted from March 2020 to August 2022, including all patients hospitalized consecutively with VAP and concomitant bloodstream infection due to CRAB in the COVID-ICU. The main goal of the study was to evaluate risk factors associated with survival or death at 30 days from VAP onset. A propensity score for receiving therapy was added to the model.
RESULTS: during the study period, 73 patients who developed VAP and concomitant positive blood cultures caused by CRAB were enrolled in the COVID-ICU. Of these patients, 67 (91.7%) developed septic shock, 42 (57.5%) died at 14 days and 59 (80.8%) died at 30 days. Overall, 54 (74%) patients were treated with a colistin-containing regimen and 19 (26%) with a cefiderocol-containing regimen. COX regression analysis showed that COPD, and age were independently associated with 30-day mortality. Conversely, cefiderocol-containing regimens and the combination of a cefiderocol plus fosfomycin-containing regimen were independently associated with 30-day survival, as confirmed by propensity score analysis.
CONCLUSIONS: this real-life study in patients with bacteremic VAP caused by CRAB provides useful suggestions for clinicians, showing a possible benefit of cefiderocol and its association with fosfomycin.
PMID:37088438 | DOI:10.1016/j.ijantimicag.2023.106825